India's BDR Pharma seeks licence to sell version of Bristol-Myers Squibb cancer drug
MUMBAI, March 18
MUMBAI, March 18 (Reuters) - India's BDR Pharmaceuticals International Pvt Ltd has applied to the Indian patents office, seeking permission to sell a generic version of Bristol-Myers Squibb Co's cancer drug, dasatinib, through a so-called compulsory licence mechanism, a BDR executive said on Monday.
Under a global Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, countries can issue compulsory licences for certain drugs that are deemed unaffordable to a large section of their populations.
Early this month, Bayer AG lost an appeal challenging the first-ever compulsory licence issued by India which allowed Natco Pharma to sell a version of the German drugmaker's cancer treatment Nexavar.
- Alabama man gets $1,000 in police settlement, his lawyers get $459,000
- Doctor with Ebola in New York hospital after return from Guinea |
- New York police officer critically wounded in hatchet attack
- Exclusive: Charred tanks in Ukraine point to Russian involvement
- Ground offensive against Islamic State months away in Iraq: U.S.